Supreme Court Judge Recused From Glivec Patent Case In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India